OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with
placebo as treatment for major depressive disorder (MDD) in adult females.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA